Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BioCorRx (BICX) Long-Term Deferred Tax (2016 - 2024)

Historic Long-Term Deferred Tax for BioCorRx (BICX) over the last 13 years, with Q4 2024 value amounting to $12.4 million.

  • BioCorRx's Long-Term Deferred Tax rose 839.06% to $12.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was $12.4 million, marking a year-over-year increase of 839.06%. This contributed to the annual value of $12.4 million for FY2024, which is 839.06% up from last year.
  • According to the latest figures from Q4 2024, BioCorRx's Long-Term Deferred Tax is $12.4 million, which was up 839.06% from $11.4 million recorded in Q4 2023.
  • BioCorRx's Long-Term Deferred Tax's 5-year high stood at $12.4 million during Q4 2024, with a 5-year trough of $7.2 million in Q4 2020.
  • Its 5-year average for Long-Term Deferred Tax is $10.3 million, with a median of $10.7 million in 2022.
  • Per our database at Business Quant, BioCorRx's Long-Term Deferred Tax skyrocketed by 3562.66% in 2021 and then soared by 681.72% in 2023.
  • Over the past 5 years, BioCorRx's Long-Term Deferred Tax (Quarter) stood at $7.2 million in 2020, then surged by 35.63% to $9.8 million in 2021, then grew by 9.13% to $10.7 million in 2022, then grew by 6.82% to $11.4 million in 2023, then grew by 8.39% to $12.4 million in 2024.
  • Its Long-Term Deferred Tax was $12.4 million in Q4 2024, compared to $11.4 million in Q4 2023 and $10.7 million in Q4 2022.